Trial Profile

A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pexmetinib (Primary)
Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

30 Jan 2025 Planned End Date changed from 21 Nov 2027 to 16 Oct 2025.
17 Jan 2024 Planned End Date changed from 1 Jun 2027 to 21 Nov 2027.
17 Jan 2024 Planned primary completion date changed from 1 Mar 2026 to 21 Nov 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com